BenevolentAI
Helen Long is an Advanced Bioinformatics Scientist at BenevolentAI, a position held since August 2022. Prior to this role, Helen pursued joint DPhil studies at both the Big Data Institute and MRC Harwell Institute from March 2018 to August 2022, focusing on bioinformatics research. Helen obtained a Doctor of Philosophy (DPhil) from the University of Oxford between 2017 and 2021, a Master’s degree in Bioinformatics and Theoretical Systems Biology from Imperial College London in 2017, and a Bachelor's degree in Biology/Biological Sciences from the University of Oxford from 2011 to 2014.
This person is not in any teams
This person is not in any offices
BenevolentAI
8 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.